Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | METAP1 | P53582 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9023567 | 0.79 | CHRM5 (0.32) | CHRM5ADRA2CCHRM2CHRM4CHRM1 | |
| SCHEMBL4076165 | 0.71 | CETP (0.33) | — | |
| SCHEMBL7684884 | 0.69 | CYP1A2 (0.40) | CYP1A2CTSLCTSBSIGMAR1CTSD | |
| SCHEMBL5450869 | 0.68 | CYP1A2 (0.48) | CYP1A2CTSLCTSBSIGMAR1CTSD | |
| SCHEMBL15355135 | 0.68 | CYP1A2 (0.48) | CYP1A2CTSLCTSBSIGMAR1CTSD | |
| SCHEMBL6153538 | 0.68 | CYP1A2 (0.48) | CYP1A2CTSLCTSBSIGMAR1CTSD | |
| SCHEMBL10479712 | 0.67 | CYP1A2 (0.34) | CYP1A2CTSLCTSB | |
| SCHEMBL2990379 | 0.67 | CYP1A2 (0.41) | CYP1A2SIGMAR1CTSDBACE1 | |
| SCHEMBL1431683 | 0.64 | USP2 (0.37) | CYP1A2 | |
| SCHEMBL2704009 | 0.64 | CYP1A2 (0.42) | CYP1A2SIGMAR1HPGDMETAP1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6492397-B1 | SUCH AS 1-PROPYL-4-BUTYL-1,3-DIHYDRO-3-((5-(2-(1H-TETRAZOL-5-YL)PHENYL)-2 -PYRIDINYL)METHYL)-2H-IMIDAZOL-2-ONE; ANGIO-TENSIN II ANTAGONISTS; CIRCULATORY DISORDERS; HYPERTENSION, CONGESTIVE HEART FAILURE | PHARMACIA CORPORATION | 2002-12-10 | — | — | US | claimed |
| EP-0579766-B1 | N-ARYLHETEROARYLALKYL IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | SEARLE & CO (US) | 1999-06-02 | — | — | EP | claimed |
| EP-0508393-B1 | N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders | SEARLE & CO (US) | 1999-06-02 | — | — | EP | claimed |
| US-5861420-A | ANGIOTENSIN II ANTAGONISTS | G. D. SEARLE & CO. (US) | 1999-01-19 | — | — | US | claimed |
| US-5643906-A | LOWERING INTRAOCULAR PRESSURE FOR TREATMENT OF GLAUCOMA | G.D. SEARLE & CO. (US) | 1997-07-01 | — | — | US | claimed |
| US-5484937-A | ANGIOTENSIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1996-01-16 | — | — | US | claimed |
| EP-0579766-A1 | N-ARYLHETEROARYLALKYL IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1994-01-26 | — | — | EP | claimed |
| US-5175180-A | Antagonist, antagonism | G. D. SEARLE & CO. (US) | 1992-12-29 | — | — | US | claimed |
| WO-1992017469-A2 | N-ARYLHETEROARYLALKYL IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-10-15 | — | — | WO | claimed |
| EP-0508393-A1 | N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders | G.D. Searle & Co. (US) | 1992-10-14 | — | — | EP | claimed |
| WO-1992011255-A1 | N-SUBSTITUTED N-(α-TRIAZOLYL-TOLUYL)PYRROLE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-07-09 | — | — | WO | claimed |
| US-6492397-B1 | SUCH AS 1-PROPYL-4-BUTYL-1,3-DIHYDRO-3-((5-(2-(1H-TETRAZOL-5-YL)PHENYL)-2 -PYRIDINYL)METHYL)-2H-IMIDAZOL-2-ONE; ANGIO-TENSIN II ANTAGONISTS; CIRCULATORY DISORDERS; HYPERTENSION, CONGESTIVE HEART FAILURE | PHARMACIA CORPORATION | 2002-12-10 | — | — | US | disclosed |
| EP-0579766-B1 | N-ARYLHETEROARYLALKYL IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | SEARLE & CO (US) | 1999-06-02 | — | — | EP | disclosed |
| EP-0508393-B1 | N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders | SEARLE & CO (US) | 1999-06-02 | — | — | EP | disclosed |
| US-5861420-A | ANGIOTENSIN II ANTAGONISTS | G. D. SEARLE & CO. (US) | 1999-01-19 | — | — | US | disclosed |
| WO-1992017469-A2 | N-ARYLHETEROARYLALKYL IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-10-15 | — | — | WO | disclosed |
| EP-0508393-A1 | N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders | G.D. Searle & Co. (US) | 1992-10-14 | — | — | EP | disclosed |
| WO-1992011255-A1 | N-SUBSTITUTED N-(α-TRIAZOLYL-TOLUYL)PYRROLE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-07-09 | — | — | WO | disclosed |
| WO-1992007834-A1 | N-SUBSTITUTED IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-05-14 | — | — | WO | disclosed |
| US-5087634-A | N-substituted imidazol-2-one compounds for treatment of circulatory disorders | G. D. SEARLE & CO. (US) | 1992-02-11 | — | — | US | disclosed |